CYP19A1 and breast cancer: In total, 365/440 HR-positive BC patients were treated with hormonal therapy, and specifically, 131/365 (35.9%) were treated with tamoxifen, 173/365 (47.4%) received aromatase inhibitors (AI; Anastrozole, Letrozole, or Exemestane), 57/365 (15.6%) were under the regimen of two years of adjuvant therapy with tamoxifen which was then switched to AI for the next three years until the completion of a total of five years of hormonal therapy, and 4/365 (1.1%) received other hormonal therapies.